Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the ...
Please provide your email address to receive an email when new articles are posted on . NOV05 will be evaluated in patients with noninfectious anterior uveitis. Novaliq plans to initiate a phase 2 ...
Unlike existing therapies that primarily suppress symptoms through hormonal modulation, ENDO-205 is the first candidate in development designed to eliminate endometriosis lesions and address ...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX016, an investigational ...
The ongoing Phase II study (DL-VSU-201) has recently been amended to include a co-primary efficacy endpoint to support product registration based on recent FDA discussions. Data from both the Phase II ...
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech ...
Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next ...
Cartography Biosciences, Inc., a biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has ...
The US Food and Drug Administration (FDA) has submitted its budget proposal to Congress, outlining its spending priorities ...
TBS-2025 to be investigated in combination with a menin inhibitor in mutNPM1 r/r AML TAMPA, Fla., Feb. 17, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (HURA) ("TuHURA" or the "Company"), a Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results